GlassScriptPhysician profile
Ambreen Ansari
NPI 1780045310
$538.89
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.27 · 2022: $42.73 · 2023: $142 · 2024: $199 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $116.61 | 2021-2025 | Mounjaro, Zepbound, Reyvow |
| Astellas Pharma US INC | $78.34 | 2022-2024 | Veozah, Myrbetriq |
| Corcept Therapeutics | $63.10 | 2024-2025 | Korlym |
| Pfizer INC. | $49.88 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $47.02 | 2022-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $31.79 | 2024 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $22.04 | 2023 | Nuedexta |
| Sanofi Pasteur INC. | $21.39 | 2023 | |
| Exact Sciences Corporation | $18.04 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $18.00 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.83 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $15.39 | 2024 | |
| Radius Health, INC. | $14.99 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $13.76 | 2023 | Verquvo, Steglatro, Belsomra |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.